Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Back to Quotes search
NVONovo Nordisk A/S Live data
$40.70▲ +0.01 (0.0%)as of Nov 11, 2026, 6:10 PM UTC
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$35.12$64.16
1-Month Range
Month up 6.9%
$38.06$42.18
Daily Price Range
Day up 0.0%
$40.10$40.80
Volume
vs 12M avg
6M12M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$135.6B
Short % of Float—
Employees—
Sales$309,064M
Shares Outstanding3,333,483,124
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.nvo.com
Novo Nordisk A/S — Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dos….· via yahoo
Warnings
1 signal
Live
- Current ratio below 1 (0.84)
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
91
Growth
47
Quality
95
Sentiment
45
Insider Sent.
—
Piotroski F
—
Altman Z
—
Consensus rating unavailable — no analyst coverage on file for NVO.
Price targets unavailable — no 12-month targets on file for NVO.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on NVO, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedNov 11, 2026, 6:10 PM UTC